Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-09-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
绿康新能（上海）进出口贸易有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" (Audit Report and Financial Statements) for the company 绿康新能（上海）进出口贸易有限公司 covering the fiscal year 2024 and the period January to May 2025. It includes an audit opinion, detailed financial statements such as balance sheets, income statements, cash flow statements, and notes to the financial statements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of an audit opinion and detailed financial data confirms this is a standalone audit report with financial statements, not a full annual report (10-K) or interim report (IR). The document is not a certification or a short announcement but a comprehensive audit report with financial statements and notes. Therefore, the correct classification is Audit Report / Information (AR). Q2 2025
2025-09-23 Chinese
绿康生化股份有限公司重大资产出售暨关联交易报告书（草案）（修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产出售暨关联交易报告书（草案）（修订稿）摘要" which translates to "Major Asset Sale and Related Party Transaction Report (Draft) (Revised) Summary." It is a detailed report concerning a significant asset disposal and related party transaction by the company, including background, transaction details, financial impact, decision procedures, risk disclosures, and commitments by management and shareholders. The document includes financial data, transaction specifics, and legal and regulatory compliance statements. It is not a simple announcement or a brief summary but a comprehensive report on a major asset sale and related party transaction. This type of document fits the category of a Capital/Financing Update (CAP) because it deals with significant changes in the company's asset structure and related transactions affecting capital. It is not an Annual Report, Interim Report, or Audit Report, nor is it a simple announcement or voting result. Therefore, the most appropriate classification is CAP with high confidence.
2025-09-23 Chinese
绿康（玉山）胶膜材料有限公司等3家公司评估报告（银信评报字（2025）第C00092号）
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" which translates to "Asset Valuation Report" or "Asset Appraisal Report." It is prepared by an asset evaluation company and details the valuation of shareholder equity of three companies related to 绿康生化股份有限公司 (Lvkang Biochemical Co., Ltd.) as of December 31, 2024. The report includes detailed financial data, valuation methods, assumptions, and conclusions. It is a comprehensive standalone asset appraisal report, not an announcement or a summary. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a specialized audit or valuation report related to asset appraisal. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2024
2025-09-23 Chinese
第五届董事会独立董事专门会议第十次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of directors of a company regarding approval of matters related to a major asset sale and related transactions. It includes voting results and approval of audit reports, asset evaluation reports, and agreements related to the transaction. The content focuses on board/management decisions and approvals rather than financial results, earnings, or regulatory filings. It is not an annual report, earnings release, or audit report by itself, nor is it a general regulatory filing or announcement of a report. The document is clearly about board-level decisions and approvals, fitting the category of Board/Management Information (MANG). The document length is short and it is a meeting resolution, not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2025-09-23 Chinese
北京市竞天公诚律师事务所关于绿康生化股份有限公司重大资产出售暨关联交易相关内幕信息知情人买卖股票情况的自查报告的专项核查意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion report issued by a law firm regarding the investigation of insider trading activities related to a major asset sale and related party transaction by the company. It includes detailed information about the investigation period, scope, and findings on insider trading activities by various parties. The document references specific regulatory requirements and legal standards but does not contain financial statements or typical financial report content. It is a specialized legal proceeding report related to a significant transaction and insider trading compliance, not an annual report, audit report, or earnings release. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 4010 characters, which is relatively short but contains substantive legal content rather than a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2025-09-23 Chinese
浙商证券股份有限公司关于深圳证券交易所《关于对绿康生化股份有限公司重大资产出售的问询函》回复之核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed response from an independent financial advisor to an inquiry letter from the Shenzhen Stock Exchange regarding a major asset sale by a listed company, including extensive financial analysis, asset impairment testing, valuation methods, and market environment discussion. It contains substantive financial data, valuation assumptions, and detailed asset impairment calculations related to a significant transaction. The document is not a brief announcement or a certification letter but a comprehensive financial and valuation report related to a major asset disposal and related regulatory inquiry. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit/valuation report addressing regulatory questions about a major asset sale, including accounting principles and impairment testing, but is not a full annual report or interim report. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-09-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.